U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
OSAKA, Japan and CAMBRIDGE, Massachusetts, February 10, 2026 – Takeda (TSE:4502/NYSE:TAK) today announced that the U.S.......





